NuCana Valuation

Is NCNA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NCNA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NCNA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NCNA's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for NCNA?

Key metric: As NCNA is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for NCNA. This is calculated by dividing NCNA's market cap by their current book value.
What is NCNA's PB Ratio?
PB Ratio0.6x
BookUK£3.80m
Market CapUK£2.21m

Price to Book Ratio vs Peers

How does NCNA's PB Ratio compare to its peers?

The above table shows the PB ratio for NCNA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average0.8x
ADTX Aditxt
0.6xn/aUS$3.0m
FRES Fresh2 Group
0.2xn/aUS$2.9m
MTNB Matinas BioPharma Holdings
0.2x71.9%US$3.1m
LIPO Lipella Pharmaceuticals
2.2x3.3%US$3.2m
NCNA NuCana
0.6x10.2%US$2.8m

Price-To-Book vs Peers: NCNA is good value based on its Price-To-Book Ratio (0.6x) compared to the peer average (0.8x).


Price to Book Ratio vs Industry

How does NCNA's PB Ratio compare vs other companies in the US Biotechs Industry?

61 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$554.58m
IMAB I-Mab
0.4x1.8%US$76.59m
ACET Adicet Bio
0.4x6.7%US$74.16m
MGX Metagenomi
0.3x-23.2%US$70.73m
NCNA 0.6xIndustry Avg. 1.9xNo. of Companies81PB01.63.24.86.48+
61 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: NCNA is good value based on its Price-To-Book Ratio (0.6x) compared to the US Biotechs industry average (1.9x).


Price to Book Ratio vs Fair Ratio

What is NCNA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NCNA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NCNA's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NCNA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.23
US$49.67
+3,937.9%
77.5%US$104.00US$20.00n/a3
Nov ’25US$1.54
US$49.67
+3,125.1%
77.5%US$104.00US$20.00n/a3
Oct ’25US$2.06
US$93.00
+4,414.6%
55.5%US$150.00US$25.00n/a3
Sep ’25US$3.66
US$134.67
+3,579.4%
16.1%US$150.00US$104.00n/a3
Aug ’25US$3.66
US$225.67
+6,074.2%
47.4%US$377.00US$150.00n/a3
Jul ’25US$2.77
US$209.00
+7,445.1%
57.7%US$377.00US$100.00n/a3
Jun ’25US$3.61
US$209.00
+5,689.5%
57.7%US$377.00US$100.00n/a3
May ’25US$3.98
US$119.83
+2,910.9%
18.1%US$150.00US$100.00n/a3
Apr ’25US$5.93
US$119.83
+1,922.5%
18.1%US$150.00US$100.00n/a3
Mar ’25US$8.00
US$110.92
+1,286.5%
25.7%US$150.00US$82.75n/a3
Feb ’25US$7.98
US$110.92
+1,290.8%
25.7%US$150.00US$82.75n/a3
Jan ’25US$7.40
US$110.92
+1,399.9%
25.7%US$150.00US$82.75n/a3
Dec ’24US$10.50
US$110.92
+956.3%
25.7%US$150.00US$82.75n/a3
Nov ’24US$11.75
US$110.92
+844.0%
25.7%US$150.00US$82.75US$1.543
Oct ’24US$15.25
US$109.42
+617.5%
27.5%US$150.00US$78.25US$2.063
Sep ’24US$16.00
US$109.42
+583.7%
27.5%US$150.00US$78.25US$3.663
Aug ’24US$18.75
US$109.42
+483.6%
27.5%US$150.00US$78.25US$3.663
Jul ’24US$19.75
US$109.42
+454.0%
27.5%US$150.00US$78.25US$2.773
Jun ’24US$21.25
US$109.42
+414.9%
27.5%US$150.00US$78.25US$3.613
May ’24US$20.25
US$109.42
+440.3%
27.5%US$150.00US$78.25US$3.983
Apr ’24US$24.00
US$99.44
+314.3%
31.3%US$150.00US$72.75US$5.934
Mar ’24US$34.00
US$94.50
+177.9%
38.2%US$150.00US$53.00US$8.004
Feb ’24US$39.50
US$85.60
+116.7%
43.1%US$150.00US$50.00US$7.985
Jan ’24US$16.50
US$85.60
+418.8%
43.1%US$150.00US$50.00US$7.405
Dec ’23US$20.63
US$85.60
+314.9%
43.1%US$150.00US$50.00US$10.505
Nov ’23US$27.00
US$106.45
+294.3%
32.5%US$150.00US$57.25US$11.755

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies